v3.26.1
Income Tax (Details Narrative) - USD ($)
5 Months Ended 12 Months Ended
Jul. 04, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2025
Jul. 31, 2025
Dec. 31, 2024
Jul. 31, 2024
Parent Company [Member]              
Income tax likelihood percentage description   greater than 50 percent     greater than 50 percent    
Statutory federal income tax rate   21.00% 21.00%   21.00%   21.00%
Operating loss carryforwards not subject to expiration   $ 2,100,000   $ 2,100,000 $ 2,100,000    
Reduce taxable income percentage description   net operating losses can only be used to reduce taxable income by 80 percent.     net operating losses can only be used to reduce taxable income by 80 percent.    
Deferred tax assets, valuation allowance   $ 3,904,000 $ 3,800,000 3,904,000 $ 3,904,000 $ 3,800,000 $ 3,848,000
Increase (decrease) in valuation allowance   56,000 (313,000)   56,000   (313,000)
Income taxes paid   $ 0 $ 0   $ 0   $ 0
Effective tax rate      
Parent Company [Member] | Federal and State Jurisdiction [Member]              
Net operating loss carryforwards   $ 15,500,000   15,500,000 $ 15,000,000.0    
Parent Company [Member] | Income Tax Jurisdiction, Foreign [Member]              
Net operating loss carryforwards   100,000   $ 100,000 $ 100,000    
Gravitics Inc [Member]              
Statutory federal income tax rate       21.00%   21.00%  
Net operating loss carryforwards   23,600,000 $ 14,200,000 $ 23,600,000   $ 14,200,000  
Deferred tax assets, valuation allowance   6,081,000 4,487,000 6,081,000   4,487,000  
Increase (decrease) in valuation allowance       $ 1,600,000   $ 1,100,000  
Effective tax rate       0.00%   0.00%  
Research and development tax credits   $ 23,000 $ 23,000 $ 23,000   $ 23,000  
Income tax description the One Big Beautiful Bill Act (“OBBBA”) was enacted in the United States. The legislation includes significant corporate tax reforms, including the permanent reinstatement of the ability to deduct domestic research and development expenditures as incurred beginning in fiscal 2025, replacing the previous requirement to capitalize and amortize such expenditures over five years. As part of OBBBA, the law changed such that all the R&D costs that were required to be capitalized from 2022 through 2024 can (1) be 100% deducted in 2025, (2) be 50% deducted in 2025 and 50% deducted in 2026, or (3) be deducted over the remaining years per the original amortization schedule. Foreign R&D expenditures are still required to be capitalized and amortized over a period of fifteen years. The Company did not accelerate deductions related to previously capitalized domestic R&D expenditures and continues to amortize such amounts over their original five-year recovery period.